Comparison of esophageal cancer survival after neoadjuvant chemoradiotherapy plus surgery versus definitive chemoradiotherapy: A systematic review and meta-analysis

医学 放化疗 食管癌 荟萃分析 肿瘤科 新辅助治疗 内科学 癌症 总体生存率 乳腺癌
作者
Junli Ke,Yujie Xie,Shen-Yang Huang,Wei Wang,Zhengang Zhao,Wanli Lin
出处
期刊:Asian Journal of Surgery [Elsevier]
卷期号:47 (9): 3827-3840
标识
DOI:10.1016/j.asjsur.2024.02.099
摘要

Surgery after neoadjuvant chemoradiotherapy remains the gold standard for the treatment of resectable esophageal cancer (EC); however, chemoradiotherapy without surgery has been recommended in specific cases. The aim of this meta-analysis is to analyse the survival between surgeries after neoadjuvant chemoradiotherapy compared with definitive chemoradiotherapy in order to provide a theoretical basis for clinically individualised differential treatment. We conducted an initial search of MEDLINE (PubMed), the Cochrane Library, and Embase for English-only articles that compared treatment regimens and provided survival data. According to the final I2 value of the two survival indicators, the random effect model or fixed effect model was used to calculate the overall hazard ratio (HR) and 95% confidence intervals (CI). Cochrane's Q test was used to judge the heterogeneity of the studies, and a funnel plot was used to evaluate for publication bias. A sensitivity analysis was performed to verify the stability of the included studies. A total of 38 studies involving 29161 patients (neoadjuvant therapy: 15401, definitive chemoradiotherapy: 13760) were included in the analysis. The final pooled results (HR = 0.74, 95% CI: 0.67–0.82) showed a statistically significant increase in overall survival with neoadjuvant chemoradiotherapy plus surgery compared with definitive chemoradiotherapy. Subgroup analyses were performed to determine the effects of heterogeneity, additional treatment regimens, study types, and geographic regions, as well as histologic differences, complications, and recurrence, on the overall results. For people with esophageal cancer that can be removed, neoadjuvant chemoradiotherapy combined with surgery improves survival compared to definitive chemoradiotherapy. However, more research is needed to confirm these results and help doctors make decisions about treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
呆萌幼晴完成签到,获得积分10
刚刚
qinqiny完成签到 ,获得积分10
1秒前
1秒前
周小慧完成签到,获得积分20
1秒前
轻松的人龙完成签到,获得积分20
1秒前
小蘑菇应助yxf采纳,获得10
1秒前
1199关注了科研通微信公众号
1秒前
星辰大海应助小赞芽采纳,获得10
1秒前
郑开司09发布了新的文献求助10
2秒前
溪与芮行完成签到 ,获得积分10
2秒前
QS完成签到,获得积分10
2秒前
彭于晏应助Stanley采纳,获得10
4秒前
小二郎应助Stanley采纳,获得10
4秒前
扑通扑通通完成签到 ,获得积分10
4秒前
lgh完成签到,获得积分10
5秒前
研友_ZAVod8发布了新的文献求助10
5秒前
5秒前
打打应助贤惠的豪英采纳,获得10
6秒前
仙子狗尾巴花完成签到,获得积分10
6秒前
虎咪咪完成签到,获得积分10
6秒前
liyi发布了新的文献求助10
6秒前
悠旷完成签到 ,获得积分10
6秒前
dingdong完成签到,获得积分20
6秒前
6秒前
科研通AI5应助凤凰山采纳,获得10
6秒前
碱性沉默完成签到,获得积分10
6秒前
晓晖完成签到,获得积分10
7秒前
7秒前
www完成签到,获得积分10
7秒前
俏皮的悟空完成签到,获得积分10
8秒前
DTT发布了新的文献求助10
9秒前
jiayueiyang发布了新的文献求助10
9秒前
研友_VZG7GZ应助lynn_zhang采纳,获得10
9秒前
9秒前
10秒前
星辰大海应助公西元柏采纳,获得10
10秒前
orixero应助Yangpc采纳,获得10
10秒前
11秒前
11秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527742
求助须知:如何正确求助?哪些是违规求助? 3107867
关于积分的说明 9286956
捐赠科研通 2805612
什么是DOI,文献DOI怎么找? 1540026
邀请新用户注册赠送积分活动 716884
科研通“疑难数据库(出版商)”最低求助积分说明 709762